Li Y - Search Results

1

CD147/EMMPRIN and CD44 are potential therapeutic targets for metastatic prostate cancer.

Hao JL, Cozzi PJ, Khatri A, Power CA, Li Y. Hao JL, et al. Among authors: li y. Curr Cancer Drug Targets. 2010 May;10(3):287-306. doi: 10.2174/156800910791190193. Curr Cancer Drug Targets. 2010. PMID: 20370680 Review.

2

MUC1 is a promising therapeutic target for prostate cancer therapy.

Li Y, Cozzi PJ. Li Y, et al. Curr Cancer Drug Targets. 2007 May;7(3):259-71. doi: 10.2174/156800907780618338. Curr Cancer Drug Targets. 2007. PMID: 17504123 Review.

3

Targeting uPA/uPAR in prostate cancer.

Li Y, Cozzi PJ. Li Y, et al. Cancer Treat Rev. 2007 Oct;33(6):521-7. doi: 10.1016/j.ctrv.2007.06.003. Epub 2007 Jul 19. Cancer Treat Rev. 2007. PMID: 17658220 Review.

4

Co-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression.

Hao J, Chen H, Madigan MC, Cozzi PJ, Beretov J, Xiao W, Delprado WJ, Russell PJ, Li Y. Hao J, et al. Among authors: li y. Br J Cancer. 2010 Sep 28;103(7):1008-18. doi: 10.1038/sj.bjc.6605839. Epub 2010 Aug 24. Br J Cancer. 2010. PMID: 20736947 Free PMC article.

5

Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance.

Chang L, Graham PH, Hao J, Ni J, Bucci J, Cozzi PJ, Kearsley JH, Li Y. Chang L, et al. Among authors: li y. Cell Death Dis. 2013 Oct 24;4(10):e875. doi: 10.1038/cddis.2013.407. Cell Death Dis. 2013. PMID: 24157869 Free PMC article.

6

PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways.

Chang L, Graham PH, Hao J, Ni J, Bucci J, Cozzi PJ, Kearsley JH, Li Y. Chang L, et al. Among authors: li y. Cell Death Dis. 2014 Oct 2;5(10):e1437. doi: 10.1038/cddis.2014.415. Cell Death Dis. 2014. PMID: 25275598 Free PMC article.

7

Immunohistochemical characterisation of the monoclonal antibody BLCA-38 for the detection of prostate cancer.

Russell PJ, Ow KT, Tam PN, Juarez J, Kingsley EA, Qu CF, Li Y, Cozzi PJ, Martiniello-Wilks R. Russell PJ, et al. Among authors: li y. Cancer Immunol Immunother. 2004 Nov;53(11):995-1004. doi: 10.1007/s00262-004-0527-7. Epub 2004 Jul 28. Cancer Immunol Immunother. 2004. PMID: 15449043 Free PMC article.

8

213Bi-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model.

Li Y, Rizvi SM, Ranson M, Allen BJ. Li Y, et al. Br J Cancer. 2002 Apr 8;86(7):1197-203. doi: 10.1038/sj.bjc.6600179. Br J Cancer. 2002. PMID: 11953871 Free PMC article.

9

MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by (213)Bi-C595 radioimmunoconjugate.

Qu CF, Li Y, Song YJ, Rizvi SM, Raja C, Zhang D, Samra J, Smith R, Perkins AC, Apostolidis C, Allen BJ. Qu CF, et al. Among authors: li y. Br J Cancer. 2004 Dec 13;91(12):2086-93. doi: 10.1038/sj.bjc.6602232. Br J Cancer. 2004. PMID: 15599383 Free PMC article.

10

Preclinical studies of targeted alpha therapy for breast cancer using 213Bi-labelled-plasminogen activator inhibitor type 2.

Allen BJ, Tian Z, Rizvi SM, Li Y, Ranson M. Allen BJ, et al. Among authors: li y. Br J Cancer. 2003 Mar 24;88(6):944-50. doi: 10.1038/sj.bjc.6600838. Br J Cancer. 2003. PMID: 12644835 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

238,409 results

Search Page

Filters